Regulatory compliance with standards and regulations can easily be regarded as a restriction on freedom and corporate individuality. Unfortunately, humans create the need for regulatory standards, purely because there will always be a situation where trust and freedom is exploited in the quest for excessive profit. There is always the perception that profit will be the first and foremost objective of your business, and that a failure in compliance is the point of no return. The reality can be much different. Complying with regulations and standards is a complex, ever-changing business with many different moving targets across all sectors of industry.

That’s not to say it’s impossible to establish compliance, only that the nature of profit seeking tends to make it difficult, if it is not the foremost thing on the agenda — which it rarely is. Legal and compliance departments do not generate profit or earnings, so why would it be? The compromise between a threadbare compliance function that is regularly playing catch-up and a state-of-the-art compliance function is a regulatory compliance reporting necessity.

CBD hemp oil is made from high-CBD, low-THC hemp, unlike medical marijuana products, which are usually made from plants with high concentrations of psychoactive tetrahydrocannabinol (THC). Because hemp contains only trace amounts of THC, these hemp oil products are non-psychoactive.

Cannabidiol (CBD) is just one of over 85 cannabinoids presently identified in the cannabis plant and is the second most abundant cannabinoid in marijuana after THC. In hemp, however, THC is only present in trace amounts, while CBD dominates the plant’s makeup. 

CBD interacts with our naturally occurring systems, but is non-psychotropic, it doesn’t cause a high.

This makes it a safer, less controversial alternative, while still offering significant health benefits.

It should be noted that CBD oil law and regulations for medical and recreational use of hemp and cannabis are constantly changing in most countries around the world. As the medical potential of both plants increases, most countries have started to reduce the legal restrictions on cultivation, production, distribution, sales, classification and taxation on hemp, cannabis and its derived products.